Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
Background Checkpoint inhibitor immunotherapy is becoming an effective treatment modality for an increasing number of malignancies. As a result, autoinflammatory side-effects are also being observed more commonly in the clinic. We are currently unable to predict which patients will develop more seve...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMJ Publishing Group
2016-12-01
|
| Serier: | Journal for ImmunoTherapy of Cancer |
| Online adgang: | https://jitc.bmj.com/content/4/1/89.full |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|